ArQule, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
      • ADMET

Other Names/Subsidiaries

  • Cyclis Pharmaceuticals, Inc.
See more in Biomedtracker

Latest on ArQule, Inc.

Scrip

Portage Buys Tarus, Gaining Cancer Assets Targeting Immune Evasion

 
• By Jessica Merrill

Portage Biotech Inc. will expand its clinical stage immuno-oncology pipeline with the addition of two adenosine receptor antagonists through the acquisition of Tarus Therapeutics. Publicly traded Port

Scrip

Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use

 
• By John Davis

Key priorities for Switzerland’s Basilea Pharmaceutica Ltd. this year include pursuing the US Phase III study of the fifth-generation cephalosporin ceftobiprole in serious infections, obtaining inte

Scrip

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

 
• By Alaric DeArment

New data from Loxo Oncology at Lilly has shown that its Bruton’s tyrosine kinase (BTK) inhibitor, LOXO-305, produces high response rates among mantle cell lymphoma (MCL) patients who have previously r

Scrip

Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL

 
• By Alaric DeArment

Phase I/II data for at Eli Lilly and Company ’s non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, LOXO-305, show a high response rate among patients with chronic lymphocytic leukemia and small l